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Autoimmune chronic active hepatitis (CAH-A) is a 
chronic liver disease of unknown etiology that is believed 
to bave an autoimmune pathogenesis. The disease is 
slowly progressive until hepatic failure and portal hy-
pertension develop and either death or liver transplan-
tation occur. Currently, the only widely recognized ther-
apy is the administration of glucocorticoids, which have 
both anti-inflammatory and immunosuppressive ac-
tions. Many patients cannot tolerate such therapy be-
cause of the psychiatric. osteoporotic, and weight-
enhancing actions of steroids. Tacrolimus (FK 506) is a 
new macrolide antibiotic that has an immunosuppres-
sive activity that is estimated to be 10-200 times greater 
than that of cyclosporine. Because of its greater immu-
nosuppressive activity, we have used it in the treatment 
of 21 patients with autoimmune chronic active hepatitis. 
Before each subject was treated. a liver biops~D and a 
panel of hematological. serological, and biochemical pa-
rameters were assessed. The Tacrolimus was adminis-
tered orally at 12-h inten'als. and the dose was con-
trolled b} monitoring plasma FK trough levels. After 3 
months of therapy at an oral dose of 3 mg twice a day. 
having achieved a median blood level of 0.5 nglml. the 
serum AL T level was reduced by 80%. and the AST level 
was reduced by 70%. Modest change in the white blood 
cell count and platelet count were noted. The median 
BUN level increased from a level of 12 to 18 mgldl. and 
the serum creatinine increased from 0.9 to 1.3 mgldl. 
These preliminar~D data demonstrate that: 1) Tacrolimus 
tan be used to succcssfulh' treat CAH-A; 2) the response 
of CAH-A to qacrolimu~ treatment is rapid and sus-
tained: and 3) a minor increase in the serum Btl!'; and 
creatinine levels occurs as a consequence of Tacrolimus 
treatment. It is anticipated that with continued treat-
ment for periods of 1-2 Jr. the natural histoQ' of CAH-A 
~ilg be changed such that hepatic failure and the re-
qUirement for liver transplantation ma~ he a\·erted. 
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INTRODUCTION 
Autoimmune chronic active hepatitis (CAH-A) is a 
chronic disorder of the liver characterized by hepatocellular 
injury and the development of a mixed macro-micronodular 
cirrhosis associated with the presence of a variety of auto-
immune serological markers. including any combination of 
the following: antinuclear antibody (ANA). anti-smooth 
muscle (ASM), anti-thyroglobulin (AT) and liver or kidney 
microsomal (LKM) autoantibodies. a polyclonal gammopa-
thy, human histocompatibility leukocyte antigens (HLA) 
and antigens 88 and Dr3 (1-19). The disease can occur in 
individuals of either gender but is four times more common 
in women than in men and can clinically present either as a 
chronic hepatitis with or without cirrhosis in the teenage 
vears or as an established cirrhosis in an adult patient (1-6). 
. The specific etiology of CAH-A is unknown. hut its 
association with HLA antigens 88 and Dr3 and a panoply of 
autoantibodies suggest that it is a consequencl' ul an abnor-
mal immune response directed at liver cells in response to a 
common viral agent or other environmental factor (9-21). 
Because of its presumed autoimmune etiology. a variety of 
immunosuppressive agents have been used in its clinical 
management (22-32). These include glucocorticoids. meth-
otrexate. azathioprine. cyclophosphamide. d-penicillamine. 
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IlIiTI<II Clinical Characteristics of Ihe PaTh'lIls SllIdil'd 
maram~ter Normal 
Total Bilirubin (mg'oll '::.0 :!: 0.7 <1.2 
AST (ll' t I 22-1 :!: 47 <32 
ALT (Ill t) 2-18 :!: HI <32 
Alkaline Phosphatase (li'/) 210 :!: -II <125 
WBC ('< Hr') 5.1 :!: 0.8 5-10 
Platelet ('< 10-') 1851:-14 15G-)O() 
BUN (mg;dl) 12.6 1: 1.9 5-20 
Creatinine (mg/dl) 0.91:0.1 <\.2 
cyclosporin A. and, in the present preliminary report, Ta-
crolimus (FK 506). The use of Tacrolimus for patients with 
CAH-A has not been reported previously. 
METHODS 
Suhjects 
A total of 21 subjects with a histological and serologically 
confirmed diagnosis of CAH-A were studied. Each subject 
had a liver biopsy consistent with the diagnosis (7, 8) and 
had one Qr more autoantibodies known to be associated with 
300 
250 _ 
200 
, 
~ 
E 160 
(.:J 
(/) 
f-
...J 
~ 100 
50 
ALT 
o ~----~f--____ ~f ______ ~f ______ ~f ______ ~f __ 
o 90 180 270 365 
Time on FK506 (days) 
AlG - 1/01. 90. ,Yo. 5. /995 
CAH-A. In addition. five were HLA B8-positive, and six 
were Dr3-positivc, All subjects gave their informed, written 
consent for their participation in this study. Moreover, this 
study was approved by the committee evaluating human 
studies at the University of Pittsburgh before its initiation. 
Pre therapy evaluation 
Each subject underwent a thorough pretherapy evaluation 
that included the following studies: 
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1 Complete blood count with platelet count: 
2 A panel of liver injury and function parameters to 
include total bilirubin, AL T, AST, alkaline phos-
phatase (alk phos), y glutamyl transpeptidase (GGPT), 
a serum electrophoresis, and a prothrombin time: 
3 A percutaneous liver biopsy for histological evaluation 
and quantitation of the hepatic iron and copper content; 
4 A cr scan of the liver for determination of liver 
volume: 
5 An ultrasound c \amination of the liver to determine the 
status of the liver, biliary tree, and portal and hepatic 
vessels: 
6 A panel of autoantibodies to include ANA. ASM. AT, 
and LKM. 
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FIG. 1. Serum ALT anJ AST levels at entry anJ 3-month intervals after starting Tacroltmus therapy. qh~ POInlS represent mean values: the hmckt'IS 
represent Ihe SEM. 
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FIG. 2. Serum bilirubin and alkaline phosphatase levels at entry and at 3-month intervals while on Tacrolimus. The points represent mean values: the 
bracket~ represent the SEM. 
Patient monitoring 
After the pretherapy evaluation procedures were completed. 
each subject was given Tacrolimus at a starting dose of 0.075 
mg/kg taken orally as equally divided doses 12 h apart. The 
initial dose was increased or reduced al 2-wk intervals to 
achieve a trough serum Tacrolimus level of 0.6-1.0 nglm!. All 
qacrolimu~ serum levels were obtained after an ove~ight fast 
and before the next morning's dose (33). Initially. all subjects 
were seen weekly (approximateh· 4 visits). then bi-weeklv 
EO-~ visits). then monthly (2-3 viSits). and finally. quarterly. 
until a I-yr study period was completed. 
At each visit. the following studies were obtained: 1) Com-
plete blood count with platelet count: 2) Electrolvtes. BUN. 
creatinine. blood sugar: 3) A liver injury panel consisting of the 
serum bilirubin. ALT. AST. alk phos. and yGTP levels: 4) A 
serum tacrolimus level. At the end of a full vear on the drug. 
all of the studies perfonned as part of the pr~study evaluati;n 
were repealed. All liver hiopsies were read b~· staff pathologists 
at the University of Pittsburgh who were blinded to the nature 
of this study a~d the timing- of the biopsies. 
Statistical anal"sls 
All resuIts are presented as mean value ::- SEM. All data 
were compared usinc the entr\' and exit measure~K The S _.
tudent·~ one-tailed t test was used for stattsllcal analysi~K A 
P Value <(l.U:' was considered significant. . 
RESULTS 
A total of 21 subjects were enrolled in the open-label 
preliminary study evaluating the efficacy and toxicity of 
Tacrolimus in the treatment of CAH-A. The demographic 
data available on these 21 patients are shown in Table 1. As 
expected. most patients were women. More than half had 
one or another marker of an abnormal immune response 
(autoantibody) and were positive for the HLA antigens B8. 
Dr3. and DrBW52. The clinical characteristics :)f these 
same patients are shown in Table 2. Most had clinical 
jaundice, and all had markedly elevated ALT and AST 
levels. The patients hematological parameters and renal 
function measures were normal. The time to achieve a stable 
serum Tacrolimus level between 0.6 and 1.0 ng'ml and to 
maintain renal function at acceptable levels was 3.0 ::- 0.5 
wk. The mean Tacrolimus dose prescrihed on a daily hasis 
at this plateau level was 7.2 =: (UI mg.'da\'. and tht.' mean 
daily dose on a per kg. basis wa~ U.06 =: (l.(JI mgkg'day. 
As a result of the Tacrolimus trealment. the AL T and 
AST kyels fell dramatically. as shown in Figure I. Simi-
larly. the serum total bilirubin level declined to a normal 
value (Fig. 2). The alkaline phosphatase level declined also 
but to a lesser degree and less consistently. probabl\" be-
cause of the high ralt: lIt" established cirrhosis in the popu-
lations studied (Fig . .:: and Table II. The changes in the 
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white blood cell counts and the platelet counts observed 
with Tacrolimus therapy are shown in Figure 3. The minor 
increase in BUN and creatinine observed with Tacrolimus 
therapy is shown in Figure .+. 
DISCUSSION 
CAH-A is a chronic hepatitis characterized histologically 
as showing piecemeal necrosis with a mononuclear infiltrate 
that consists predominantly of plasma cells and lympho-
cytes (1-8). Pathophysiologically. the disease is thought to 
represent an example of antibody-dependant cellular cyto-
toxicity mediated predominantly hy natural killer cells (34-
40). Individuals with this disease are thought to have an 
underlying genetic defect that makes them susceptible to an 
abnormal immune response to an environmental agent. ei-
ther a virus (measles. cytomegalo virus or other) and to 
develop antibodies directed at a cross-reacting antigen or 
liver cells that enable natural killer cells to attack and kill 
antibody-coated hepatocytes (9-21 l. 
In most studies. the serum AST and the degree of histolog-
ical activity have been shown to he related (7. S). This rela-
tionship between the serum AST level and the severity of the 
histological disease process is most apparent early in the dis-
ease course and is less strong as the disease progresses to 
cirrhosis and. ultimately. decompensated cirrhosis. Moreover, 
the histological disease is the parameter of disease severity that 
requires the longest time to correct with therapy. occurring 
weeks to months after clinical and biochemical resolution of 
disease (n. 30). Even with excellent clinical (suhjective) and 
biochemical evidence for disease remission. half of the pa-
tients. when biopsied after 2 yr of glucocorticoid thcrapy either 
alone or in combination with azathioprine. will show continued 
disease activity. These latter paticnts aie generally .:ontinued 
on immunosuppressive thcrapy lifelong (.+ 1-4--n. 
Because of conccms about lifelong treatment of patients. the 
majority of whom are women and are. as a result. susccptihlc 
to enhanced rates of osteoporosis with glucocorticoids. some 
patient with CAH-A have been treated with cyclosporinc A 
(CyA) (31). This latter agent is a more specific T cell specific 
immunosuppressive agent and has been used because of lis 
powerful inhibitory effects on CD4 - lymphocytes. Specifi-
cally. CyA reduces interleukin-2 (IL-2) production and [1.·2 
receptor expression on T lymphocytes and powerfully 'iUp-
presses overall immune reactivity. presumably including that 
due to antibody-dependent cellular cytotoxicity. which is 
thought to be the mechanism responsible for liver cell IIIJury 
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FIG, 4. Serum creatinine and BUN kveb in the patients treated with Tacrolimus tor C AH-A. The dose and hlood Icvd of Tacrollmus achieved is also 
shown. The {JOiIl1.1 r"present mean values: the hrackc/.I represent the SEM. 
and death in CAH-A, Preliminary trials with CyA have been 
promising but have heen limited hy the nephrotoxicity associ-
ated with its use (.31), 
Tacrolimus is a new macrolide antihiotic with immunosup-
pressive activity that is reponed to he 100-1000 times more 
POwerful on a molecular hasis than CyA when treated in 
various in I'itro assay svstems (4,)). Clinicallv. Tacrolimus has 
been shown to he ~se-ful in organ allograft recipients when 
CyA either has not worked or its usc has neen limited hv 
nephrotoxicity or some other manifestation of drug Il1xicity. 
such as hvpcncnsion or neurotoxicity E~-K:DiKPFI 
~D" 
The present study was Initiated to determine whether or 
not TacT()limus could he used in cases of CAH-A ttl ontain 
COntrol of the diseasl' process and if so. at what cost in terms 
of its nephrotoxlCit\. neurotoxicity, and diahett'p.cnic activ-
Ity? As i!. readily apparent from the data pre~ented in Fig-
Ures 1-4. Tacrolimus can he used effectivel\' III treal 
CAli-A. Moreowr. thc CllSI of such treatment i~ lerms of 
the nephrolOxicit\ of chronic T<lcr(lltmus <luministration at 
the doses and k~cls used in this stud\' arc not particularly 
~sere (Fig. -n and thl'rclure not lil~tlingI Srecificalh. a 
greater than 7')7r reduction in ongoing hepatic injury as 
manifested h\' the serum levels of AST and AL T was noted 
with Tacrolimus therapy (Fig. 1), Moreover. a substantial 
improvement in hepatic function. as manifested h\' the de-
cline to normal of the serum hiliruhin leveL was observed 
with continued Tacrolimus treatment (Fig. ~FK 
The change in renal function ohserved as a result of 
Tacrolimus treatment was minor and at no time limited 
therapy (Fig, -+), 
These results suggest that Tacrolimus should he used in a 
randomized control study against prednisone to define its 
clinical efficacy against thc hest availahle l'urrcllt therapy, 
Reprlnl requests and correspondence (),I\itl H. \an Thiel. M.D .. EF~fa­
homa Transnianl I"S(lllIle. Ibpus( Meull'al (enter 01 ()i,L1hnma .. ~Dfef 
'orth"esi L:\pre"wa,I, ll~lahElma Eff~K ()t-; ~K; II: 
REFERENCES 
I. t-;un\..l'1 11(;. \hrl'nb Lli Jr. I:tsl'nml'n!!l'r WJ. I 'Hem" hvpcf!!amma-
!!il,huhnc:mw. In \ oun~ ,,"omen \\ Hh 11\ l'r di~fK·"f~lD ul un~nown etiology. 
J Cltn In\est gDf~1:P11:EFKD4-lg 
I 
II' 
, . 
; I II 
I 
I 
I! 11 
776 V AN THIEL et aI. 
2. Wilcox RG. Isselbacher IU. Chronic liver disease in young people. 
Clinical features and course of 33 patients. Am J Med 11)61:30: 185-45. 
3. Mackav IR. Autoimmune hepatitis: An etiology in the spectrum of 
chronic active liver disease. J Gastroenterol Hepatol IQQ(1:5:352-7. 
4. Hodges JR. Millward-Sadler GH. Wright R. Chronic active hepatitis: 
The spectrum of disease. Lancet 1482:1:550-2. 
5. Keating JJ. O·Brien C1. Stellon AJ. et al. Inlluencc of aetiology. 
clinical and histological features on survival in chronic active hepatitis: 
An analysis of 204 patients. Q J Med 1987:02:59-06. 
6. Galbraith RM. Smith M. Mackenzie RM. Tee DE. Doniach D. Wil-
liams R. High prevalence of serOimmunologic abnormalities in rela-
tives of patients with active chronic hepatitis or primary biliary cir-
rhosis. N Engl J Med 1974:290:63-9. 
7. Baggenstoss AH. Soloway RD. Summerskill WHJ. Chronic active 
liver disease: The range of histologic lesions. their responses to treat-
ment and evolution. Hum Pat hoi 1472:3: 183-98. 
8. Dienes HP. Popper H. Manns M. Histologic features in autoimmune 
hepatitis. Z Gastroenterology 1989:27:325-30. 
9. Mackay IR. Morris PJ. Association of autoimmune active chronic 
hepatitis with HLA-A1.8. Lancet 1972:2:793-5. 
to. Whittingham S. Mathews 10. Schanfield MS. Tait BD. Mackay IR. 
Interaction of HLA and Gm in autoimmune chronic active hepatitis. 
Clin Exp Immunol 1981;43:80-0. 
II. Nouri-Aria KT. Donaldson PT. Hegarty lE. EddIeston AL WF. Wil-
liams R. HLA AI·B8-DR3 and suppressor cdl function in first degree 
relatives of patients with autoimmune chronic active hepatitis. J Hepa-
tol 1485: 1:235-41. 
12. Krawitt EL. Kilby AE. Albertini RJ. Immunogenetic studies of auto-
immune chronic active hepatitis. HLA. immunoglobulin allotypes and 
autoantIbodies. Hepatology 1487:7: 1305-10. 
13. lohnson Pl. Macfarlane (G. McFarlane BM. Williams R. Autoimmune 
features in patients with idiopathic chronic active h~patitis who are 
seronegative for conventional autoantibodies. 1 Gastroenterol Hepatol 
1990:5:244-51. 
14. Gurian LE. Regoff TM. Ware N. The immunologic diagnosis of 
chronic autOimmune hepalltis distinction from systemic lupus ery-
thematosus. Hepatology 1985:5:397-40:. 
15. Wood JR. Czaja AF. Beaver S1. Frequency and significance of anti-
body to double strand~d DNA in chronic active hepatitis. Hepalology 
1486:6:970-80. 
10. Homberg l-C. Abuaf N. Bernard O. et al. Chronic active hepatitis 
Clssociated with anti·liverikidney microsome antibodv type L A second 
type of ··autoimmune·· hepatitis. Hepatology 1987:7: 1333-4. 
17. Manns MP. Johnson EF. Griffin KJ. The major antigen of liver kidney 
microsomal autoantibodies in idiopathic autoimmune hepatitis is cy· 
tochrome p450 dbl. 1 Clin Invest 1989;83:1066-12. 
18. Treichel U. Panalla T. Hess G. Autoantibodies to human asialoglyco-
protein receptor in autoimmune·type chronic hepatitis. Hepatology 
1990; 11:006-12. 
19. Wachter B. Kyriatsoulis A. Lohse AW. Characterization of liver cy-
tokeratin as a major antigen of anti HLA antibodi.:s. 1 Hepatology 
19<JO: 11:232-9. 
20. Robertson OAF. Zhang SL. Guy EC, Wright R. Persistent measl<!s 
virus genome in autoimmune chronic active hepatitis. Lancet 1487: I: 
4-11. 
21. ChristIe KE. Haukenes G. M~asles virus sp<!cific precipitins in sera 
from patients with chronic active h<!patitis. Scand 1 Infect Dis 1979: 
11:99-106. 
Read AE. Sherlock S. Harrison CV. Active ··Juve:1lle·· cirrhosis con-
sidered as part of a systemic dis<!ase and the effect of corticosteroid 
therapy. Gut 1963:4:378 -93. 
23. Cop<!nhagen Study Group for Liver Disease. Effect of prednisone on 
the survival of patients with cirrhosis of the liver. Lmcet I %9: I: 114-
21. 
24. Cook GL. Mulligan R. Sherlock S. Controllt:d prospective trial of 
corticosteroid therapy in active chronic hepatitis. Q J Med 1971 AO: 
159-85. 
25. Solowav RD. Summerskill WH1. Baggenstoss A. Clinical biochemical 
and histological remission in severe chronic active liver disease: A 
controlled study of treatment and earlv prognosis. Gastroenterology 
147:!:1l3:820-33. 
26. Murrav Lvon 1M. Stem RB. Williams R. Controlled trial of pred· 
nisolo~e a·nd azathioprine in active chronic hepatitis. Lancet 1973:2: 
735-7. 
AlG - Vol. 90. No.5, 1995 
27. Kirk AP. lain S. Pocock S. Late results of the Royal Free Hospital 
prospective controlled trial of prednisolone therapy in hepatitis B 
surface antigen negative chronic active hepatitis. Gut 1980:21: 78-83. 
28. Czaja N. Davis GL. Ludwig J. Autoimmune features as determinanta 
of prognosIs in steroid chronic active hepatitis of uncertain etiology. 
Gastroenterology I Q83:85: 713-7. 
29. Davis GL. Czaja AL. Ludwig J. Development and prognosis of hIS-
tologic cirrhosis in corticosteroid treated hepatitis B surface antigen 
negative chronic active hepatitis. Gastroenterology 1984:87: 1222-7. 
30. Czaja N. Davis GL. Ludwig 1. Taswell HF. Complete resolution of 
intlammatory activity following corticosteroid treatment of HBsAg 
negative chronic active hepatitis. Hepatology 1984:4:622-7. 
31. Mistilis SP. Vickers CR. Darroch MH. McCarthy SW. Cyclosporin. a 
new treatment for autoimmune chronic active hepatitis. Med 1 Austr 
1985;143:463-5. 
32. Mistilis SP. Blackburn CRB. The treatment of active chronic hepatitis 
with 6-mercaptopurine and azathioprine. Austr Ann Med 1967;16: 
305-11. 
33. Kobayashi M. Tamura K. Katayama N. et 31. FK 506 assay past 3Dd 
present. Characteristics of FK 500 ELISA. Transplant Proc 1991;23: 
2725-9. 
34. Mondelli M. Eddleston AL WF. Lymphocyte cytotoxicity for autolo-
gous hepatocytes. Gut 1984:25:109-13. 
35. Manns MP. Nakamura RM. Autoimmune liver disease. Clin Lab Mcd 
1988;8:281-301. 
36. Wen L. Peakman M. Lobo-Yeo A. Evidence that circulating activated 
T cell lymphocytes direct the immune attack on the liver cells in 
autoimmune chronic active hepatitis. Lancet 1990:330: 1521-30. 
37. Vento S. Eddleston ALWF. Immunological aspects of chronic active 
hepatitis. Clin Exp Immunol 1987:68:225-32. 
38. Vergani GM. Vergani D. lenkins Pl. et al. Lymphocyte cytotoxicity to 
autologous hepatocytes in HBsAg negative chromc active hepatitis. 
Clin bp Immunol 1979:38:16-21. 
39. Eggink HF. Howthoff HJ. Huitema S. Cellular and humeral reactions 
in chronic active liver disease. I. Clin Exp Immunol 1982:50: 17-24. 
40. PoraHa T. Ramadori G, Dienes HP. Liver cell damage caused bv 
monoclonal antibody against an organ specific membr;ne anugen i~ 
vivo and in ~ itro. 1 Hepatology 19H7:4:373-80. 
~ I. Czaja AJ. Ludwig 1. Baggenstoss AH. Wolf A. Corticosteroid-treated 
chronic active hepatitis in remission. N Engl 1 Med 1481:304:5-<J. 
42. Hegarty lE. Nouri Aria KT. Portmann B. Eddlcslon ALWF. Williams 
R. Relapse following treatment withdrawal in patients with autoim-
mune chronic active hepatitis. Hepatology 1983;3:085-9. 
43. de Groote l. Fevery 1. Lepoutre L. Long-term follow·up of chronic 
active hepatitis of moderate severity. Gut 1978: 19:510-3. 
44. Schalm SW. Ammon HV. Summerskill WHJ. Failure of customary 
treatment in chronic active liver disease: Causes and management. Ann 
C1in Res 1976:8:221-7. 
45. Kobayashi M. Tamura K. Katayama N. et al. FK 506 assay past and 
present: Characteristics of FK 506 ELISA Transplant Proc 1941;23: 
2725-9. 
46. Fung J. Abu-Elmagd K. Jain A. et al. A randomized trial of primary 
liver transplantation under immunosuppression with FK SOl) vs cyclo-
sporine. Transplant Proc 1991;23:2477-83. 
47. Winkler M. Ringe B. Gerstenkom C. Rodeck B. Gubernatis G. Woni-
geit K. et al. Use of FK 506 for treatment of chronic rejection after liver 
transplantation. Transplant Proc 11)41 :23:2984-6. 
4H. D· Alessandro AM. Kalavoglu M. Pirsch 10. et at. FK 50ll rescue 
therapy for resistant rejection episodes in liver transplant reCIpients. 
Transplant Proc 1491:23:2987-8. 
50. 
51. 
52. 
53. 
Shaw BW Jr. Markin R. Stratla R. Langnas A. Donovan 1. Sorrell M. 
FK 50b rescue treatment of acute and chronic rejection in liver al· 
lograft recipients. Transplant Proc 1991 :23:2994 -5. 
McDiarmid SV. K1intmalm G. Busuttil RW. FK 501l rescue therapy in 
liver transplantation: Outcome and complications. Transplant Proc 
1491 :23:21)96-9. 
Demetris A.I. Fung JJ. Todo S. et al. FK 500 used as rescue therapv for 
human liver allograft recipIents. Transplant Proc 149J::!3:3005-o. 
Mieles LA. Fung JJ. Yokoyama l. et al. Liver transplantation of 
American veterans under FK 500 immunosuppression: A preliminary 
report. Transplant Proc 1991 :23:3010-8. 
Takava S. Bronsther O. Todo S. et al. Retransplantation of liver: A 
comparison of FK 500- and cyclosporine-treated patients. fransplanl 
Proc 1941:2.3:3026-K. 
, - .•. P h 4 .... 
